| |  Online-Ressource |
|---|
| Verfasst von: | Hasseli-Fräbel, Rebecca [VerfasserIn]  |
|---|
| | Hanses, Frank [VerfasserIn] |
|---|
| | Stecher, Melanie [VerfasserIn] |
|---|
| | Specker, Christof [VerfasserIn] |
|---|
| | Weise, Tobias [VerfasserIn] |
|---|
| | Borgmann, Stefan [VerfasserIn] |
|---|
| | Hasselberger, Martina [VerfasserIn] |
|---|
| | Hertenstein, Bernd [VerfasserIn] |
|---|
| | Hower, Martin [VerfasserIn] |
|---|
| | Hoyer, Bimba F. [VerfasserIn] |
|---|
| | Koll, Carolin [VerfasserIn] |
|---|
| | Krause, Andreas [VerfasserIn] |
|---|
| | von Lilienfeld-Toal, Marie [VerfasserIn] |
|---|
| | Lorenz, Hanns-Martin [VerfasserIn] |
|---|
| | Merle, Uta [VerfasserIn] |
|---|
| | Nunes de Miranda, Susana Marina [VerfasserIn] |
|---|
| | Pletz, Mathias W. [VerfasserIn] |
|---|
| | Regierer, Anne C. [VerfasserIn] |
|---|
| | Richter, Jutta G. [VerfasserIn] |
|---|
| | Rieg, Siegbert [VerfasserIn] |
|---|
| | Roemmele, Christoph [VerfasserIn] |
|---|
| | Ruethrich, Maria M. [VerfasserIn] |
|---|
| | Schmeiser, Tim [VerfasserIn] |
|---|
| | Schulze-Koops, Hendrik [VerfasserIn] |
|---|
| | Strangfeld, Anja [VerfasserIn] |
|---|
| | Vehreschild, Maria J. G. T. [VerfasserIn] |
|---|
| | Voit, Florian [VerfasserIn] |
|---|
| | Voll, Reinhard [VerfasserIn] |
|---|
| | Vehreschild, Jörg Janne [VerfasserIn] |
|---|
| | Müller-Ladner, Ulf [VerfasserIn] |
|---|
| | Pfeil, Alexander [VerfasserIn] |
|---|
| Titel: | The protective effect of tumor necrosis factor-alpha inhibitors in COVID-19 in patients with inflammatory rheumatic diseases compared to the general population - a comparison of two German registries |
|---|
| Verf.angabe: | Rebecca Hasseli, Frank Hanses, Melanie Stecher, Christof Specker, Tobias Weise, Stefan Borgmann, Martina Hasselberger, Bernd Hertenstein, Martin Hower, Bimba F. Hoyer, Carolin Koll, Andreas Krause, Marie von Lilienfeld-Toal, Hanns-Martin Lorenz, Uta Merle, Susana M. Nunes de Miranda, Mathias W. Pletz, Anne C. Regierer, Jutta G. Richter, Siegbert Rieg, Christoph Roemmele, Maria M. Ruethrich, Tim Schmeiser, Hendrik Schulze-Koops, Anja Strangfeld, Maria J.G.T. Vehreschild, Florian Voit, Reinhard E. Voll, Jörg Janne Vehreschild, Ulf Müller-Ladner and Alexander Pfeil |
|---|
| E-Jahr: | 2024 |
|---|
| Jahr: | 06 March 2024 |
|---|
| Umfang: | 12 S. |
|---|
| Illustrationen: | Illustrationen |
|---|
| Fussnoten: | Gesehen am 11.09.2024 |
|---|
| Titel Quelle: | Enthalten in: Frontiers in medicine |
|---|
| Ort Quelle: | Lausanne : Frontiers Media, 2014 |
|---|
| Jahr Quelle: | 2024 |
|---|
| Band/Heft Quelle: | 11(2024), Artikel-ID 1332716, Seite 1-12 |
|---|
| ISSN Quelle: | 2296-858X |
|---|
| Abstract: | Objectives: To investigate, whether inflammatory rheumatic diseases (IRD) inpatients are at higher risk to develop a severe course of SARS-CoV-2 infections compared to the general population, data from the German COVID-19 registry for IRD patients and data from the Lean European Survey on SARS-CoV-2 (LEOSS) infected patients covering inpatients from the general population with SARS-CoV-2 infections were compared. Methods: 4310 (LEOSS registry) and 1139 cases (IRD registry) were collected in general. Data were matched for age and gender. From both registries, 732 matched inpatients (LEOSS registry: n> = 366 and IRD registry: n = 366) were included for analyses in total. Results: Regarding the COVID-19 associated lethality, no significant difference between both registries was observed. Age > 65°years, chronic obstructive pulmonary disease, diabetes mellitus, rheumatoid arthritis, spondyloarthritis and the use of rituximab were associated with more severe courses of COVID-19. Female gender and the use of tumor necrosis factor-alpha inhibitors (TNF-I) were associated with a better outcome of COVID-19. Conclusion: Inflammatory rheumatic diseases (IRD) patients have the same risk factors for severe COVID-19 regarding comorbidities compared to the general population without any immune-mediated disease or immunomodulation. The use of rituximab was associated with an increased risk for severe COVID-19. On the other hand, the use of TNF-I was associated with less severe COVID-19 compared to the general population, which might indicate a protective effect of TNF-I against severe COVID-19 disease. |
|---|
| DOI: | doi:10.3389/fmed.2024.1332716 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
kostenfrei: Volltext: https://doi.org/10.3389/fmed.2024.1332716 |
|---|
| | kostenfrei: Volltext: https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1332716/full |
|---|
| | DOI: https://doi.org/10.3389/fmed.2024.1332716 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | COVID-19 |
|---|
| | general population |
|---|
| | Inflammatory rheumatic diseases |
|---|
| | Severe disease |
|---|
| | Tumor necrosis factor-alpha inhibitors |
|---|
| K10plus-PPN: | 1902345037 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
¬The¬ protective effect of tumor necrosis factor-alpha inhibitors in COVID-19 in patients with inflammatory rheumatic diseases compared to the general population - a comparison of two German registries / Hasseli-Fräbel, Rebecca [VerfasserIn]; 06 March 2024 (Online-Ressource)
